Backgrounds/Aims: Combined hepatocellular carcinoma and cholangiocarcinoma (cHCC-CC) is an uncommon subtype of primary liver cancer that has rarely been reported in detail. This study was performed in order to evaluate the clinicopathological characteristics and prognostic factors of cHCC-CC in single center. Methods: The clinicopathological fea¬tures of patients diagnosed and operated with cHCC-CC at Chonbuk National Hospital between July 1998 and July 2007 were retrospectively studied by comparing them with patients with only hepatocellular carcinoma (HCC) who had undergone a hepatic resection during the same period. Results: Ten out of 152 patients who had undergone a hepatic resection were diagnosed with cHCC-CC and thus included in this study (M : F=8 : 2, median age: 52±11.1 years). According to the parameters of the 7th American Joint Committee on Cancer T staging, there were 76 (50.0%), 44 (28.9%), 9 (5.9%), 18 (11.8%) and 5 (3.3%) patients with T stages 1, 2, 3a, 3b and 4, respectively. The overall survival period was longer in the HCC only group (68±40.4 months) than in the combined cHCC-CC group (23±40.1 months) (p＜0.0001). The 5-year survival rate was 10% in the cHCC-CC group and 60% in the HCC group (p＜0.0001). The disease free survival for patients with cHCC-HCC and HCC were 16±37.4 and 51±44.3 months, respectively (p ＜0.0001). Univariate analysis revealed that age, gender, transarterial chemoembolization (TACE), and T stage were statistically significant in terms of patient's overall survival. However, there were no significant clinicopathological factors identified by the multivariate analysis. Conclusions: Even after the hepatic resection in the HCC, the prognosis is poorer if the patient has cholangiocellular components compared to the usual HCC. 
INTRODUCTION

METHODS
Patients
A total of 152 patients with primary liver cancer, except CC, underwent hepatic resection between July 1, 1998 and July 31, 2007 at Chonbuk National University Hospital. The overall survival of the cHCC-CC group was lower than the HCC group (p＜0.0001). 1-year, 3-year and 5-year survival rates in the HCC group were 82%, 73% and 60%, respectively. On the other hand, the cHCC-CC group showed downward results with 1-year, 3-year and 5-year survival rates at 20%, 20% and 10%, respectively. (p＜0.000) Mean survival period in the HCC and cHCC-CC groups were 68±40.4 and 23±40.1 months, respectively.
Fig. 2.
Disease free survival of patients with HCC and cHCC-CC. The disease free survival of the cHCC-CC group was lower than the HCC group (p＜0.0001). 1-year, 3-year and 5-year disease free survival rates in the HCC group were 67%, 59% and 50%, respectively. On the other hand, the cHCC-CC group showed 1-year, 3-year and 5-year survival rates of 10%, 10% and 10%, respectively (p＜0.0001).
(15.5%) (p=0.003). The prevalence of the hepatitis B surface antigen was found in 58 (40.8%) patients; positive serology for hepatitis C infection was found in 5 (3.5%)
patients. Alcoholic liver cirrhosis was found in 10 (7%)
patients. The hepatitis B surface antigen with alcoholic liver cirrhosis was found in 1 (0.7%) patient (Table 1 ).
The median level of AFP was 2,997 ng/ml (1.6-875,000 In the cHCC-CC (n=10) group, the median age was 52 years (39-70); there were 8 men (80%) and 2 women (20%). The prevalence of the hepatitis B surface antigen was 8 (80%).
The median level of AFP was 9,361 ng/ml (5.4-75680).
Postoperative TACE was conducted in 3 (30%) patients.
There were 2 (20.0%), 3 (30.0%), 1 (10%), 3(30%) and 1 (10%) patients with T stages 1, 2, 3a, 3b and 4, respectively.
There was no significant difference between the HCC and cHCC-CC group based on the clinicopathological factors.
Overall and disease-free survival rate of patients with HCC and cHCC-CC
The 1-year overall survival rate was 82%, the 3-year overall survival rate was 73%, and the 5-year overall survival rate was 60% in the HCC group. On the other hand, the cHCC-CC group showed that the 1-year overall survival rate was 20%, the 3-year overall survival rate was 20%, and the 5-year overall survival rate was 10% (p=0.000). Median survival periods in the HCC and cHCC-CC groups were 68±40.4 and 23±40.1 months, respectively ( Fig. 1 ).
In the HCC group, the 1-year disease free survival rate was 67%, the 3-year disease free survival rate was 59%, and the 5-year disease free survival rate was 50%. On the other hand, the cHCC-CC group indicated that the 1-year disease free survival rate was 10%, the 3-year disease free survival rate was 10%, and the 5-year disease free survival rate was 10% (p＜0.0001).
Except for 1 case in which the patient survived for 122 months at the T1 stage, most patients in the cHCC-CC group died or experienced recurrence within 1 year (Fig.   2 ). According to the overall survival rate, significant prognostic factors in the cHCC-CC group were age (p=0.005), (Table 2 ).
According to the disease free survival rate, significant prognostic factors in the cHCC-CC group were age (p= 0.006), sex (p=0.046), preoperative alanine transaminase (ALT) (p=0.03) and T stage (p=0.005) in the univariate analysis, but not in the multivariate analysis (Table 3) .
DISCUSSION
cHCC-CC is an uncommon liver malignancy with distinctive features compared with HCC and CC in respect to its clinicopathologic changes and prognosis. The incidence of cHCC-CC varies widely, from a rate of 2.4% to 14.2%. 2 In our study, the incidence of cHCC-CC was 6.6%. Generally, the clinicopathological features of cHCC-CC were similar to those of HCC.
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Most cHCC-CC patients in our series were men with a high prevalence of HBV, suggesting that HBV infection is a main cause for both HCC and cHCC-CC in Asia.
According to AFP, the elevation of AFP was found in both groups. Some authors reported that high elevation of the AFP level (≥400 IU/L) was an independent prognostic factor in cHCC-CC. 5, 7 On the other hand, Jarnagin et al.
reported that the level of AFP in cHCC-CC was lower than that in HCC, but had no significant difference. 10 In our study, there was no significant difference in the AFP levels as well as in the statistical relationship with a survival rate between the HCC-CC group and the HCC group.
The number of tumor and UICC stage in cHCC-CC were predictive factors of the overall survival rate. 2 Our study demonstrated that the T stage was related to a significant difference in the survival rate in the univariate analysis, but not in multivariate analysis.
cHCC-CC patients had poorer prognosis compared to HCC patients, and CC had a relatively unfavorable prognosis compared with cHCC-CC and HCC. 5, 9 In our study, the cHCC-CC group had significantly poorer prognosis than the HCC patients. Okuda 12 reported that patient prognosis with cHCC-CC was poorer than that of HCC because lymph node metastasis occurred more frequently. In our study, the disease free survival rate was 16 months and T stage was a significant prognostic factor.
TACE is indicated for patients with non-resectable or recurrent HCC for palliative purposes because it has been proved to increase the survival of these patients. However, the therapeutic effect of TACE for cHCC-CCs remains unclear. Compared with HCC, many cHCC-CCs are less vascular than HCC and thus, may poorly respond to TACE. Other reports showed that patients in advancedstage disease cases who had received TACE treatment had a significantly longer 6-month survival than patients who received supportive treatment. 8, 13, 14 Our 3 patients who underwent TACE showed a significant improvement in the survival rate. Some studies reported radiation treatment attempts to patients with non-resectable or local recurrent tumor for a better survival rate. 15 There are some limitations in our study. First, this study was retrospective and could have been affected by any and all of the limitations of this investigational design.
Second, both HCC and cHCC-CC were compared without CC.
In conclusion, most reports have indicated that surgical intervention was an effective treatment for cHCC-CC.
However, patients with cHCC-CC have a significantly poorer survival outcome after hepatic resection than do patients with HCC. Further studies on effective treatment modalities and clinical predictors for cHCC-CC are required in order to prolong the survival of these patients.
